| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL INVESTIGATIONS |
Departments of Nuclear Medicine, Gynecology, and Pathology, Technische Universität München, Munich; Department of Gynecology, University Hospital Eppendorf, Hamburg; and Department of Pathology, Städtisches Krankenhaus München-Harlaching, Munich, Germany
Breast cancer is characterized by elevated glucose consumption resulting in increased uptake of 18F-FDG. However, tracer uptake varies considerably among tumors imaged with PET. This study compared histologic and immunohistochemical tissue analysis of breast carcinomas with preoperative FDG uptake assessed by PET to identify tumor characteristics that define the degree of tracer accumulation. Methods: FDG uptake in breast tumors was quantified by calculating standardized uptake values (SUVs) corrected for partial-volume effect and normalized to blood glucose level at the time of tracer injection. The histologic sections of 50 invasive and 6 noninvasive breast carcinomas were analyzed for histologic type, microscopic tumor growth pattern, percentage of tumor cells, presence of inflammatory cells, density of blood vessels, histopathologic grading, tumor cell proliferation (mitotic rate and antibody binding of MIB-1), expression of estrogen and progesterone receptors, and expression of the glucose transporter protein Glut-1. Results: A positive correlation was found between FDG uptake and histologic tumor type (ductal vs. lobular; P = 0.003), microscopic tumor growth pattern (nodular vs. diffuse; P = 0.007), and tumor cell proliferation (MIB-1; P = 0.009). Tumors with diffuse growth patterns had significantly lower SUVs compared with clearly defined tumors. A weak relationship was found between FDG uptake and the percentage of tumor cells (P = 0.06). Lower densities of blood vessels corresponded to higher FDG uptakes (P = 0.08). However, even significant correlations showed poor correlation coefficients. No relationship was found between FDG uptake and the following: tumor size; axillary lymph node status; percentage of necrotic, fibrotic, and cystic compounds; presence of inflammatory cells; steroid receptor status; and expression of Glut-1. Conclusion: Histologic and immunohistochemical tissue analysis was unable to sufficiently explain the variation of FDG uptake in breast cancer. The degree of metabolic changes after malignant transformation is most likely explained by a complex interaction between cellular energy demand and tumoral microenvironment. Therefore, FDG PET imaging may not be used to estimate tumor biologic behavior of breast cancer such as differentiation, histopathologic grading, cell proliferation, or axillary lymph node status.
Key Words: PET • FDG • breast cancer • metabolism • histology • immunohistochemistry
This article has been cited by other articles:
|
|
 |
|
  T. Kato, J. Shinoda, N. Nakayama, K. Miwa, A. Okumura, H. Yano, S. Yoshimura, T. Maruyama, Y. Muragaki, and T. Iwama Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline Positron-Emission Tomography AJNR Am. J. Neuroradiol., June 1, 2008; 29(6): 1176 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Beer, S. Lorenzen, S. Metz, K. Herrmann, P. Watzlowik, H.-J. Wester, C. Peschel, F. Lordick, and M. Schwaiger Comparison of Integrin {alpha}v 3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG J. Nucl. Med., January 1, 2008; 49(1): 22 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kesner, W.-A. Hsueh, N. L. Htet, B. S. Pio, J. Czernin, M. D. Pegram, M. E. Phelps, and D. H.S. Silverman Biodistribution and Predictive Value of 18F-Fluorocyclophosphamide in Mice Bearing Human Breast Cancer Xenografts J. Nucl. Med., December 1, 2007; 48(12): 2021 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kumar, N. Lal, and A. Alavi 18F-FDG PET in Detecting Primary Breast Cancer J. Nucl. Med., October 1, 2007; 48(10): 1751 - 1751. [Full Text] [PDF]
|
|
|
|
|
|
A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions J. Nucl. Med., August 1, 2007; 48(8): 1266 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Soret, S. L. Bacharach, and I. Buvat Partial-Volume Effect in PET Tumor Imaging J. Nucl. Med., June 1, 2007; 48(6): 932 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maeda, U. Tateishi, T. Hasegawa, H. Ojima, Y. Arai, and K. Sugimura Primary Hepatic Angiosarcoma on Coregistered FDG PET and CT Images Am. J. Roentgenol., June 1, 2007; 188(6): 1615 - 1617. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma Ann. Onc., November 1, 2006; 17(11): 1650 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maeda, U. Tateishi, Y. Sasajima, T. Hasegawa, H. Daisaki, Y. Arai, and K. Sugimura Atypical Polypoid Adenomyoma of the Uterus: Appearance on 18F-FDG PET/MRI Fused Images Am. J. Roentgenol., February 1, 2006; 186(2): 320 - 323. [Full Text] [PDF]
|
|
|
|
|
|
K. D. Miller, M. Miller, S. Mehrotra, B. Agarwal, B. H. Mock, Q.-H. Zheng, S. Badve, G. D. Hutchins, and G. W. Sledge Jr. A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171 Clin. Cancer Res., January 1, 2006; 12(1): 281 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Bird, L. Yan, K. M. Vrotsos, K. W. Eliceiri, E. M. Vaughan, P. J. Keely, J. G. White, and N. Ramanujam Metabolic Mapping of MCF10A Human Breast Cells via Multiphoton Fluorescence Lifetime Imaging of the Coenzyme NADH Cancer Res., October 1, 2005; 65(19): 8766 - 8773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. M. van Laarhoven, L.-F. de Geus-Oei, B. Wiering, J. Lok, M. Rijpkema, J. H. A. M. Kaanders, P. F. M. Krabbe, T. Ruers, C. J. A. Punt, A. J. van der Kogel, et al. Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET Radiology, October 1, 2005; 237(1): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, L. Liau, P. Mischel, J. Czernin, M. E. Phelps, and D. H.S. Silverman Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG J. Nucl. Med., June 1, 2005; 46(6): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Rosen, T. G. Turkington, M. S. Soo, J. A. Baker, and R. E. Coleman Detection of Primary Breast Carcinoma with a Dedicated, Large-Field-of-View FDG PET Mammography Device: Initial Experience Radiology, February 1, 2005; 234(2): 527 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro, and S. h. Kang Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy Ann. Onc., September 1, 2004; 15(9): 1352 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kumar, S. Mitchell, A. Alavi, J. Czernin, and D. Vranjesevic 18F-FDG Uptake and Breast Density in Women with Normal Breast Tissue J. Nucl. Med., August 1, 2004; 45(8): 1423 - 1424. [Full Text] [PDF]
|
|
|
|
|
|
N. Avril GLUT1 Expression in Tissue and 18F-FDG Uptake J. Nucl. Med., June 1, 2004; 45(6): 930 - 932. [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Chung, K.-J. Cho, S.-S. Lee, H. J. Baek, J.-H. Park, G. J. Cheon, C.-W. Choi, and S. M. Lim Overexpression of Glut1 in Lymphoid Follicles Correlates with False-Positive 18F-FDG PET Results in Lung Cancer Staging J. Nucl. Med., June 1, 2004; 45(6): 999 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck and S. N. Reske Cellular Origin and Molecular Mechanisms of 18F-FDG Uptake: Is There a Contribution of the Endothelium? J. Nucl. Med., March 1, 2004; 45(3): 461 - 463. [Full Text]
|
|
|
|
|
|
T.-C. Yen, L.-C. See, C.-H. Lai, C. W. Yah-Huei, K.-K. Ng, S.-Y. Ma, W.-J. Lin, J.-T. Chen, W.-J. Chen, C.-R. Lai, et al. 18F-FDG Uptake in Squamous Cell Carcinoma of the Cervix Is Correlated with Glucose Transporter 1 Expression J. Nucl. Med., January 1, 2004; 45(1): 22 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith Clinical Role of FDG PET in Evaluation of Cancer Patients RadioGraphics, March 1, 2003; 23(2): 315 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kaarstad, D. Bender, L. Bentzen, O. L. Munk, and S. Keiding Metabolic Fate of 18F-FDG in Mice Bearing Either SCCVII Squamous Cell Carcinoma or C3H Mammary Carcinoma J. Nucl. Med., July 1, 2002; 43(7): 940 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vranjesevic, J. E. Filmont, J. Meta, D. H. Silverman, M. E. Phelps, J. Rao, P. E. Valk, and J. Czernin Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients J. Nucl. Med., March 1, 2002; 43(3): 325 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bos, J. J.M. van der Hoeven, E. van der Wall, P. van der Groep, P. J. van Diest, E. F.I. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, et al. Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography J. Clin. Oncol., January 15, 2002; 20(2): 379 - 387. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
